miR-132 is a widely expressed regulatory RNA in the cardiovascular system.When miR-132 is highly expressed in cardiac tissues,it will affect the signaling pathways related to cardiomyocyte growth,autophagy,calcium processing and contraction,and cause progressive adverse cardiac remodeling,thus leading to heart failure events.Studies had found that targeted inhibition of miR-132 could reduce cardiac hypertrophy and improve cardiac function,bringing certain clinical benefits to patients with heart failure.CDR132L is a synthetic lead-optimized oligonucleotide inhibitor of miR-132.The efficacy and safety of CDR132L had been demonstrated for the first time in clinical trials.Antisense oligonucleotides targeting miR-132 are potential future therapies for ischemic or non-ischemic heart failure.
维普
万方数据